A Comprehensive Review of Potential Warfarin-Fruit Interactions.

PURPOSE: The aim of this review is to discuss possible interactions that may occur between warfarin and fruit products. METHODS: A literature search was conducted using the search terms: "warfarin (Coumadin®) and fruit interactions, warfarin and fruit, warfarin and fruit juice, case reports and clinical trials". RESULTS: A total of 23 citations (15 case reports and 7 controlled clinical trials) were reviewed. The majority of cases involved cranberry products, while pomegranate juice, avocado, grapefruit juice, mango, and papain were also implicated in reports of suspected warfarin-fruit interactions. Cranberry juice was also the most frequently studied fruit product. Other fruit products evaluated with warfarin in controlled clinical trials were cranberry concentrate and grapefruit juice. CONCLUSION: Although a number of case reports have been published that suggest warfarin has the potential to interact with several fruit products, it is difficult to determine their relevance, as scientific evidence is scarce. Until further information is available, clinicians may want to encourage patients to consume cranberry products and grapefruit juice in small to moderate quantities and to inquire about the recent consumption of mangos, pomegranate juice, and avocados when taking a dietary history or when assessing possible causes for international normalized ratio (INR) instability.

A survey of community pharmacists and final-year student pharmacists and their perception of psychotherapeutic agents.

INTRODUCTION: The World Health Organization has estimated that as many as 450 million people worldwide have mental disorders. More than 44 million people in the United States have a mental disorder annually, estimating the annual direct costs of mental illness to exceed US$69 billion. Psychotherapeutic agents are used to treat mental illnesses and improve quality of life. The purpose of the study is to assess the knowledge and knowledge perception of community pharmacists and final-year student pharmacists regarding psychotherapeutic agents dispensed to their community of patients with mental illness. METHODS: A survey was distributed to pharmacists and final-year student pharmacists regarding psychotherapeutic agents. RESULTS: In all, 100 pharmacists and 40 final-year student pharmacists completed the survey. Upon analysis of surveys returned by pharmacists, knowledge deficiency was assessed regarding anxiolytics and mood stabilizers. The analysis of student participant surveys demonstrated knowledge deficiency regarding antidepressants and anxiolytics. CONCLUSIONS: Final-year student pharmacists would benefit from the curricular incorporation of courses and advanced pharmacy practice experiences in Psychiatry. Community pharmacists caring for customers with psychiatric disorders should take advantage of continuing education series that highlight updates and new developments regarding psychotherapeutic agents in order to improve clinical outcomes of patients.

Aripiprazole for the treatment of adolescent Tourette's syndrome: a case report.

Gilles de la Tourette syndrome (GTS) is a neuropsychiatric, lifelong disorder with onset in childhood. The essential features of this disorder are multiple motor tics and one or more vocalizations. The neurochemical pathophysiology of GTS involves an unknown abnormality in the central dopaminergic system. Atypical antipsychotics, such as aripiprazole, serve as a new therapeutic option for GTS. The authors describe a unique case of Tourette's syndrome (TS) in an adolescent in which aripiprazole resolved the patient's symptoms. A 17-year-old, 5'11'' tall, African American male weighing 220 lbs was diagnosed with TS at 9 years old. By age 16, the patient developed prominent symptoms of intermitted eye blinking, forehead raising, finger snapping, heavy breathing, and head bobbing. Clonidine, in addition to homeopathic remedies (N-acetylcholine and alpha lipoic acid), was administered to the patient without significant diminution of symptoms. Later, aripiprazole was initiated at 5 mg/d. As a result, noticeable symptomatic improvement occurred within 48 hours. Aripiprazole was titrated over the next 4 weeks to 6.5 mg/d, with significant results. Over the next 6 months, aripiprazole was titrated again to 10 mg/d with additional symptom reduction. This case illustrates a patient who responded to aripiprazole with no reported adverse effects, when standard therapy failed to improve symptoms.

Detoxification from high-dose zolpidem using diazepam.

OBJECTIVE: To report a rare case of physical and psychological addiction to an excessive dose of zolpidem and subsequent completed detoxification using diazepam. CASE SUMMARY: A 46-year-old white man with a history of polysubstance abuse received a prescription for zolpidem 2 years prior to his hospital detoxification. During that time, he gradually escalated the total dosage to an amount of 400 mg/day in divided doses. Upon hospitalization, he was detoxified using a standard benzodiazepine 7-day diazepam tapering regimen. DISCUSSION: Zolpidem is a nonbenzodiazepine medication approved for the short-term treatment of insomnia. Its mechanism is a selective benzodiazepine type 1 receptor agonist. The selectivity of the drug for the type 1 receptor may not be absolute and is inversely dose dependent. Compared with the benzodiazepines, zolpidem addiction is rare. However, at higher than recommended doses for extended periods of time, its addictive potential may be similar to that of the benzodiazepines. CONCLUSIONS: Given the similarities in receptor binding and pharmacologic activities of zolpidem and the benzodiazepines, we chose to use a standard benzodiazepine detoxification protocol to treat zolpidem withdrawal. Confirmation of this has been evidenced by successful zolpidem detoxification using a standard 7-day benzodiazepine/diazepam taper regimen.